BR9813409A - " sal de monoargininila de ácido (e) -3-[1-n-butil-5-[2,2-carbóxi fenil) metóxi-4-clorofenil] - 1h-pirazol-4-il] -2- [ (5-metóxi-2,3 -di-hidro-benzofuran-6-il) metil ] -prop-2- enóico " - Google Patents

" sal de monoargininila de ácido (e) -3-[1-n-butil-5-[2,2-carbóxi fenil) metóxi-4-clorofenil] - 1h-pirazol-4-il] -2- [ (5-metóxi-2,3 -di-hidro-benzofuran-6-il) metil ] -prop-2- enóico "

Info

Publication number
BR9813409A
BR9813409A BR9813409-4A BR9813409A BR9813409A BR 9813409 A BR9813409 A BR 9813409A BR 9813409 A BR9813409 A BR 9813409A BR 9813409 A BR9813409 A BR 9813409A
Authority
BR
Brazil
Prior art keywords
methoxy
chlorophenyl
prop
butyl
enoic
Prior art date
Application number
BR9813409-4A
Other languages
English (en)
Inventor
Joseph Robert Flisak
Albert Stephen Kearney
Nagesh Palepu
Cherng-Yih Perng
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR9813409A publication Critical patent/BR9813409A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

''SAL DE MONOARGININILA DE áCIDO (E) -3- [1-N-BUTIL-5- [2,2-CARBóXI FENIL)METóXI-4-CLOROFENIL] -1H-PIRAZOL-4-IL] -2- [(5-METóXI-2,3-DI-HIDROBENZOFURAN-6-IL)METIL]-PROP-2-E NóICO'' A presente invenção refere-se a uma nova forma de sal de monoargininila do antagonista de receptor de endotelina, ácido (E) -3- [1-n-butil-5- [2- (2-carbóxi fenil)metóxi-4-clorofenil] -1H-pirazol-4-il] -2- [(5-metóxi-2,3-di-hidrobenzofuran-6-il)metil-prop-2-enóico.
BR9813409-4A 1997-12-08 1998-12-07 " sal de monoargininila de ácido (e) -3-[1-n-butil-5-[2,2-carbóxi fenil) metóxi-4-clorofenil] - 1h-pirazol-4-il] -2- [ (5-metóxi-2,3 -di-hidro-benzofuran-6-il) metil ] -prop-2- enóico " BR9813409A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6773297P 1997-12-08 1997-12-08
PCT/US1998/025903 WO1999029685A1 (en) 1997-12-08 1998-12-07 (e)-3-[1-n-butyl- 5-[2-(2-carboxyphenyl)methoxy- 4-chlorophenyl]-1h- pyrazol-4-yl]-2-[(5- methoxy-2,3- dihydrobenzofuran-6-yl)methyl]- prop-2-enoic acid monoargininyl salt

Publications (1)

Publication Number Publication Date
BR9813409A true BR9813409A (pt) 2000-10-10

Family

ID=22078027

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813409-4A BR9813409A (pt) 1997-12-08 1998-12-07 " sal de monoargininila de ácido (e) -3-[1-n-butil-5-[2,2-carbóxi fenil) metóxi-4-clorofenil] - 1h-pirazol-4-il] -2- [ (5-metóxi-2,3 -di-hidro-benzofuran-6-il) metil ] -prop-2- enóico "

Country Status (24)

Country Link
US (1) US6300359B1 (pt)
EP (1) EP1037888B1 (pt)
JP (1) JP2001525405A (pt)
KR (1) KR20010040292A (pt)
CN (1) CN1281447A (pt)
AR (1) AR017426A1 (pt)
AT (1) ATE223404T1 (pt)
AU (1) AU747108B2 (pt)
BR (1) BR9813409A (pt)
CA (1) CA2312965A1 (pt)
CO (1) CO5021171A1 (pt)
DE (1) DE69807745T2 (pt)
DK (1) DK1037888T3 (pt)
ES (1) ES2182383T3 (pt)
HU (1) HUP0100423A3 (pt)
IL (1) IL136592A (pt)
NO (1) NO20002904D0 (pt)
NZ (1) NZ504898A (pt)
PL (1) PL341601A1 (pt)
PT (1) PT1037888E (pt)
TR (1) TR200001633T2 (pt)
TW (1) TW505643B (pt)
WO (1) WO1999029685A1 (pt)
ZA (1) ZA9811154B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2007067779A2 (en) * 2005-12-08 2007-06-14 Tsrl, Inc. Methods and compositions for drug delivery enhancement
WO2009061805A1 (en) * 2007-11-05 2009-05-14 Scolr Pharma, Inc. Formulations for enhanced bioavailability of orally administered polar agents
US8805519B2 (en) 2010-09-30 2014-08-12 Nevro Corporation Systems and methods for detecting intrathecal penetration
US10980999B2 (en) 2017-03-09 2021-04-20 Nevro Corp. Paddle leads and delivery tools, and associated systems and methods
WO2019191423A1 (en) 2018-03-29 2019-10-03 Nevro Corp. Leads having sidewall openings, and associated systems and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
MX9800975A (es) * 1995-08-02 1998-04-30 Smithkline Beecham Corp Antagonistas de receptor de endotelina.

Also Published As

Publication number Publication date
NO20002904L (no) 2000-06-07
TR200001633T2 (tr) 2001-07-23
HK1032229A1 (en) 2001-07-13
EP1037888B1 (en) 2002-09-04
PT1037888E (pt) 2002-12-31
CN1281447A (zh) 2001-01-24
AR017426A1 (es) 2001-09-05
TW505643B (en) 2002-10-11
NO20002904D0 (no) 2000-06-07
ATE223404T1 (de) 2002-09-15
DE69807745T2 (de) 2003-05-15
ES2182383T3 (es) 2003-03-01
CO5021171A1 (es) 2001-03-27
AU1713899A (en) 1999-06-28
PL341601A1 (en) 2001-04-23
ZA9811154B (en) 1999-06-08
HUP0100423A2 (hu) 2002-05-29
HUP0100423A3 (en) 2002-08-28
IL136592A0 (en) 2001-06-14
JP2001525405A (ja) 2001-12-11
IL136592A (en) 2003-03-12
US6300359B1 (en) 2001-10-09
DK1037888T3 (da) 2003-01-06
NZ504898A (en) 2002-11-26
KR20010040292A (ko) 2001-05-15
WO1999029685A1 (en) 1999-06-17
EP1037888A4 (en) 2001-08-22
CA2312965A1 (en) 1999-06-17
AU747108B2 (en) 2002-05-09
EP1037888A1 (en) 2000-09-27
DE69807745D1 (de) 2002-10-10

Similar Documents

Publication Publication Date Title
DE69915888D1 (de) Sulfonamidverbindungen des hydroxydiphenylharnstoffs als il-8 rezeptorantagonisten
DE60022386D1 (de) Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten
EP1535179A4 (en) TRANSPARENT ROUTES OF REQUIREMENTS FOR A PARTITIONED APPLICATION SERVICE
PL402986A1 (pl) Pochodna eteru alkilowego lub jej sól, stanowiaca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól
ATE323678T1 (de) Tri-aryl-säurederivate als ppar rezeptor liganden
CY1107238T1 (el) Παρασκευη μιας πολυμορφικης μορφης ενος παραγωγου θειαζολιδινοδιονης
DE69832200D1 (de) 2,3-substituierte indolverbindungen als cox-2 inhibitoren
BR9813409A (pt) " sal de monoargininila de ácido (e) -3-[1-n-butil-5-[2,2-carbóxi fenil) metóxi-4-clorofenil] - 1h-pirazol-4-il] -2- [ (5-metóxi-2,3 -di-hidro-benzofuran-6-il) metil ] -prop-2- enóico "
ATE416173T1 (de) 1-(3 -heteroarylpropyl- oder -prop -2-enyl) -4- benzylpiperidine als nmda-rezeptor-antagonisten
ATE245653T1 (de) Imidazolverbindungen als phosphodiesterase vii- hemmer
EP1819396A4 (en) HEMODYNAMIC OPTIMIZATION SYSTEM FOR BIVENTRICULAR IMPLANTS
TR199700457A2 (xx) 3-(2-(4-(4-(amino-imino-metil)-fenil)-4-metil-2,5-diokso-
DK1384717T3 (da) 2-(2'Triphenylmethyl-2'H-tetrazol-5'-yl)phenylboronsyre som mellemprodukter til syntese af AII receptorantagonister
DK1206462T3 (da) Hererocykliske forbindelser til inhibering af angiogenese
ATE280161T1 (de) Imidazolverbindungen als alpha2-adrenorezeptoren antagonisten
FR2813932B1 (fr) Diaphragme pour mecanisme d'embrayage
FR2832718B1 (fr) Procede ameliore pour synthetiser une resine d'adhesivite
NO20015040A (no) System for automatisk distribusjon av oppdaterte opplysninger om kontakter
DE69714247D1 (de) Heterozyklische verbindungen
FR2841011B1 (fr) Systeme de decouplage pour une pedale
EP1624671A4 (en) RECORDING CONTROL SYSTEM
FR2808057B1 (fr) Diaphragme annulaire pour mecanisme d'embrayage comprenant ce diaphragme
FR2814892B1 (fr) Systeme permettant d'utiliser un ordinateur comme serveur pour televiseurs
FR2827781B1 (fr) Systeme de securite d'incendie pour cheminee domestique
EP1955185A4 (en) SYSTEM FOR IDENTIFYING THE PRESENCE OF PEER TO PEER NETWORK SOFTWARE APPLICATIONS

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.